CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
The Food and Drug Administration on Monday approved label changes to Gilead Science's nucleotide reverse transcriptase inhibitor Viread to reflect new data from an ongoing study of treatment-naive patients taking the medication as part of first-line therapy. The label was changed to include new dose recommendations for patients with kidney impairment, a new warning about HIV-hepatitis B coinfection, dose recommendations for using Viread with Videx (ddI), and updated information on the drug's effects on the body's bones. The original label stated that Viread should be taken with food, but the new label changes also say the medication can be taken without food. The new label changes state that because renal impairment, including acute renal failure and Fanconi syndrome, have been reported in patients taking Viread, doctors should avoid using the drug with or recently following the use of other drugs that affect kidney function. Patients taking Viread also should be carefully screened for underlying kidney disease before beginning the medication. Because the safety and efficacy of Viread has not been determined for HIV-positive patients also coinfected with hepatitis B, and due to reports that Viread users may experience increased hepatitis B disease progression after stopping the medication, the FDA recommends that coinfected patients be closely monitored for any signs of hepatitis complications. The use of Viread also may result in increased blood-based levels of ddI when the drugs are taken together, and adults on a Viread-ddI regimen should have their ddI dosing reduced to 250 milligrams, according to the new label changes. The new label also notes that some Viread users have experienced slight decreases in bone mineral density in the spine, hip, and arms. Bone monitoring should be considered for HIV patients who have a history of bone fracture or are at substantial risk for osteopenia.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
21+ steamy photos of Scotland’s finest gay men in Elska Glasgow
February 01 2024 10:07 PM
More Than 50 of Our Favorite LGBTQ+ Moms
May 12 2024 11:44 AM
Latest Stories
Walmart and MISTR to offer free at-home HIV testing kits
July 25 2024 10:02 AM
Joe Biden sends queer lawmakers & LGBTQ+ allies to Paris Olympics
July 24 2024 12:08 PM
Kamala Harris rides wave of Democratic energy at kickoff event in Wisconsin
July 23 2024 3:36 PM